Sigma Healthcare Ltd (ASX: SIG) released its full year report to the ASX this morning.
Sigma Healthcare is the operator of several leading pharmacy brands including Amcal, Guardian and DDS.
Here are some of the financial highlights from its full report compared to last year:
- Revenue down 5.4% to $4.13 billion
- Day to day trading, or EBITDA, up 4% to $92.8 million (click here to learn what EBITDA means)
- Profit up 3.5% to $55 million
- Dividend down 16.6% to 2.5 cents per share
Mark Hooper, Sigma’s CEO, said: “Today’s result is in line with guidance. We are working harder than ever to ensure we can grow and diversify our earnings, improve customer service and keep a close eye on costs. We are also very focused on being more aggressive on a merger & acquisition front.”
We are positioning Sigma for growth in the coming years. – Hooper
The Sigma Healthcare share price is down 1.14% in early trade according to Google Finance.
Did you know it’s free to join The Rask Group’s Investor Club Newsletter? It’s a regular (usually weekly) news and educational update on financial markets, investing and unique strategies. Join today and get ready to laugh and learn.
Click here to join The Rask Group’s Investor Club Newsletter Today
Hey, you, read this disclaimer: This article contains information only. It is not financial advice. It is no substitute for trusted and licensed financial advice and should not be relied upon. By using our website you agree to our Code of Ethics, Disclaimer & Terms of Use and Privacy Policy. Also, don’t forget, past performance is not a reliable indicator of future performance.
